期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 27, 期 2, 页码 235-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2017.11.001
关键词
Irinotecan; Oxaliplatin; 5-fluorouracil; Antiepidermal growth factor receptor antibody; Vascular endothelial growth factor antibody; Immunotherapy; Regorafenib; Trifluridine/tipiracil
Systemic treatments for patients with colon cancer has expanded broadly beyond 5-fluorouracil-based chemotherapy. For patients with early-stage colon cancer who are considering adjuvant chemotherapy, multiple factors such as the risk of disease recurrence, absolute survival benefit of chemotherapy, treatment toxicity, and patient comorbid medical conditions must be taken into account. In the metastatic setting, biomarkers such as KRAS/NRAS/BRAF mutation, microsatellite instability status, and left- versus right-sided colon cancer have helped oncologists to tailor systemic treatment regimens, which include chemotherapy, targeted therapy, and immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据